An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
The New Year is not yet three days old, but deal-hungry investors looking forward to next week’s JP Morgan conference already have a megamerger on their hands.
The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.
Pfizer and Merck & Co take increases, making it easier for others to follow. But shifts in congressional power means pricing will remain a minefield.
Lilly reduces its reliance on older products, but Roche and Sanofi still need fresh blood.
Split congressional control will result in more drug pricing talk, but don’t expect much action.